Related Experiment Video
Updated: Jun 7, 2025
09:14
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
10.8K
Resmetirom
Terri L Levien1, Danial E Baker2
1Pharmacotherapy Department, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.
Hospital Pharmacy
|November 19, 2024
Summary
The Formulary Monograph Service provides monthly drug monographs for Pharmacy and Therapeutics Committees, aiding in drug evaluation and utilization. Subscribers receive comprehensive reviews and customizable online access for informed decision-making.
Area of Science:
- Pharmaceutical sciences
- Clinical pharmacy
- Health services research
Background:
- Pharmacy and Therapeutics Committees require timely, evidence-based drug information.
- New drug approvals and late-stage trials necessitate thorough evaluation.
- Effective medication use evaluation (MUE) is crucial for patient safety and cost-effectiveness.
Purpose of the Study:
- To provide Pharmacy and Therapeutics Committees with detailed monographs on new and emerging drugs.
- To offer concise summaries for pharmacy and nursing in-services and agenda planning.
- To deliver comprehensive drug utilization evaluations (DUE/MUE) to support informed prescribing and formulary management.
Main Methods:
- Publication of 5-6 detailed monographs per month covering newly released or late-phase III trial drugs.
- Inclusion of 1-page summary monographs for quick reference and educational purposes.
- Provision of a comprehensive drug utilization evaluation/medication use evaluation (DUE/MUE) monthly.
Main Results:
- Subscribers receive consistent, well-documented drug information.
- Monographs are accessible online, with options for customization.
- Selected reviews are published in cooperation with Hospital Pharmacy.
Conclusions:
- The Formulary Monograph Service effectively supports evidence-based formulary management.
- It provides essential tools for Pharmacy and Therapeutics Committees and healthcare professionals.
- The service facilitates informed decision-making regarding drug selection and utilization.
More Related Videos
Related Concept Videos
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
146
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
146
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
244
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
244
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
174
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
174
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
135
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
135
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
237
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
237
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
527
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
527